Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Disease Modifying Therapies Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Background: Women with multiple sclerosis (MS) who become pregnant and utilize maternity services may find their use of disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...
Poster-Disease-modifying Therapy
October 25, 2021
Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database.
Background: Evidence is needed that adherence to disease-modifying therapies (DMT) for multiple sclerosis (MS) can reduce total medical...
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)
Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...
Poster-Disease-modifying Therapy
October 25, 2021
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....
Poster-Complementary and Alternative Therapies
October 25, 2021
Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS
Background: MS care provided in a comprehensive MS center improves outcomes. Well-established MS centers struggle to include complementary...